Week of May 11-17, 2026: Seven IBD research stories worth your attention
Having lived with Crohn’s since 2002, I’ve learned to scan the research landscape with a particular kind of patience. This week brought seven studies and developments across the IBD spectrum — from real-world data on biologic switching to early-stage work on compounds found in black licorice. None of it changes what I’m doing tomorrow, but several pieces add useful context to ongoing treatment conversations.
What stood out: solid real-world data from Brazil on biologic switching patterns, a systematic review on vaping that actually acknowledges its limitations, and preclinical work that’s interesting to file away but years from clinical relevance. The usual mix of “worth knowing” rather than “practice-changing.”
Real-world biologic switching patterns in Brazilian UC patients
This retrospective study from a Brazilian university hospital tracked biologic use patterns in 34 ulcerative colitis patients over an 18-month period. Infliximab was the most common first biologic (88% of patients), with 38% of patients switching biologics at least once. Allergic reactions and documented lack of response were the main switching triggers.
What this means for me right now: this kind of real-world data helps calibrate expectations around biologic durability. A 38% switching rate aligns with what I’ve observed in my own treatment journey and among other patients I know.
The main limitation: this was a single-center study with chart-based symptom tracking rather than standardized disease activity measures, so the “improvement” outcomes should be interpreted cautiously.
Systematic review finds limited evidence on vaping and IBD outcomes
Researchers conducted a systematic review of electronic nicotine delivery systems (vaping, e-cigarettes) and IBD outcomes, analyzing four observational studies covering 1,869 participants. In non-surgical settings, they found no consistent association between current vaping and major IBD outcomes. However, in post-operative Crohn’s patients, there was a signal toward higher endoscopic recurrence rates among exclusive e-cigarette users compared to non-smokers.
What this means for me right now: as someone who quit smoking years before my Crohn’s diagnosis, this reinforces that we still don’t have clear guidance on vaping for IBD patients, particularly around surgery.
The main limitation: only four studies met inclusion criteria, with small sample sizes and inconsistent exposure definitions across studies.
Perioperative strategy study shows reduced Crohn’s recurrence
A clinical study examined perioperative strategies for preventing post-surgical recurrence in Crohn’s disease. The research focused on systematic approaches to pre- and post-operative care, though specific details about the intervention and patient population weren’t available in the source summary.
What this means for me right now: having avoided surgery so far in my 24 years with Crohn’s, I file this under “important if I ever need it” rather than immediately actionable information.
The main limitation: I don’t have access to the full study details, so I can’t assess the specific interventions studied or their generalizability.
Mayo Clinic identifies ST8Sia6 molecule in treatment-resistant IBD
This preclinical research from Mayo Clinic identified a molecule called ST8Sia6 that may help explain why some IBD patients don’t respond to standard treatments. The researchers suggest this molecule could be involved in treatment resistance mechanisms, though the study appears to be in early laboratory stages.
What this means for me right now: nothing changes. This is basic science research that’s years away from any clinical application, if it ever reaches that stage.
The main limitation: preclinical findings often don’t translate to human treatments, and I don’t have details about the study methodology or validation steps.
Black licorice compound shows anti-inflammatory effects in IBD models
Researchers developed a stem cell-based model of human intestine and tested thousands of compounds for anti-inflammatory effects. They identified glycyrrhizin — a compound found in black licorice — as reducing intestinal damage and cell death in both lab-grown tissue and mouse models of IBD.
What this means for me right now: this is preclinical work that’s interesting to note but changes nothing about my current treatment approach. Lab and mouse results don’t predict human outcomes.
The main limitation: this is early-stage research using cell cultures and animal models, with no human trials yet conducted.
New York initiates clinical study on medicinal cannabis for IBD
New York’s Office of Cannabis Management launched a clinical study exploring how medicinal cannabis, specifically CBD and THC, might impact IBD symptoms. This appears to be an early-stage clinical trial, though specific details about study design, patient population, and endpoints weren’t available in the source.
What this means for me right now: clinical trials are the right way to study cannabis for IBD, but early-stage trials don’t provide treatment guidance yet.
The main limitation: without access to the study protocol, I can’t assess the rigor of the trial design or timeline for results.
Research on combination biologic therapy safety
An article covered the growing practice of “stacking” biologics — using two biologic medications simultaneously, or combining a biologic with a small molecule drug — for treating Crohn’s disease. The piece discussed who might be candidates for this approach and safety considerations.
What this means for me right now: combination therapy is something I’d discuss with my gastroenterologist if my current Rinvoq stops working effectively, but it’s not a decision I’d make based on general coverage.
The main limitation: this appears to be educational content rather than original research, so I can’t assess the underlying evidence quality.
Looking across this week’s research, what strikes me is the mix of practical real-world data (the Brazilian switching study) alongside very early-stage work that won’t affect patient care for years, if ever. After more than two decades with Crohn’s, I’ve learned to value the former while maintaining appropriate skepticism about the latter. The systematic review on vaping stands out for actually acknowledging its limitations rather than overselling weak evidence — something I wish I saw more often in IBD research coverage.
